Compare POET & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | EMBC |
|---|---|---|
| Founded | 1972 | 1924 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 843.0M | 602.3M |
| IPO Year | 2008 | 2021 |
| Metric | POET | EMBC |
|---|---|---|
| Price | $6.83 | $9.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | ★ 5.5M | 906.8K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | ★ 6.18% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | N/A |
| Revenue This Year | $2,939.08 | $1.17 |
| Revenue Next Year | $710.17 | N/A |
| P/E Ratio | ★ N/A | $13.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $9.20 |
| 52 Week High | $9.41 | $15.55 |
| Indicator | POET | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 33.73 |
| Support Level | $5.05 | $9.45 |
| Resistance Level | $7.66 | $10.88 |
| Average True Range (ATR) | 0.45 | 0.35 |
| MACD | 0.18 | -0.02 |
| Stochastic Oscillator | 76.00 | 2.67 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.